Brain Cancer | Specialty

The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Rindopepimut Plus Bevacizumab Shows Prolonged Survival in Recurrent Glioblastoma

November 15th 2014

The vaccine rindopepimut plus bevacizumab induced tumor regression in a subset of patients with recurrent glioblastoma.

Adding Lomustine to Bevacizumab Improves Outcomes in Recurrent Glioblastoma

November 14th 2014

The combination of bevacizumab and lomustine showed superior efficacy compared with either agent alone in patients with recurrent glioblastoma, warranting further study.

Dr. Verhaak Discusses Genomic Characterization of Diffuse Lower Grade Gliomas

November 14th 2014

Roeland GW Verhaak, PhD, Assistant Professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, discusses a study that examined the comprehensive and integrative genomic characterization of diffuse lower grade gliomas.

PCV Chemotherapy Plus Radiation Improves Survival in Low-Grade Glioma

November 14th 2014

The combination of radiation therapy with procarbazine, CCNU, and vincristine prolonged OS and PFS compared with radiation therapy alone in grade 2 glioma.

Dr. Toms on Targeting MEK as a Treatment Strategy for CNS Metastasis

November 14th 2014

Steven A. Toms, MD, director, neurosurgery, Geisinger Health System, discusses how targeting MEK can be an effective treatment strategy for CNS metastasis.

Dendritic Cell Vaccines Offer Promising Signals as Glioblastoma Therapy

August 29th 2014

Immunotherapy is rapidly emerging as a very attractive and novel therapeutic approach for cancer, including for glioblastoma multiforme (GBM), the most common primary malignant brain tumor in adults.

Evidence Builds for Electric Field Therapy in Recurrent GBM

August 19th 2014

A wearable device that uses electric fields to disrupt the activity of cancer cells has demonstrated survival benefits among patients with recurrent glioblastoma multiforme in real-world settings, particularly among individuals treated in earlier stages of progression

The Role of Radiation in the Management of Brain Metastases

March 6th 2014

In this review, the role of radiotherapy in the management of brain metastases is considered from a historical perspective, in the context of other treatment modalities, and with regard to different radiotherapy techniques.

Dendritic Vaccine Improves Survival in Recurrent Glioblastoma

February 19th 2014

A personalized vaccine being tested as a therapy for recurrent glioblastoma multiforme (GBM) improved patient survival compared with standard treatments

The Awake Craniotomy Presents Advantages in Resection of Eloquent Cortex Brain Tumors

January 15th 2014

Awake craniotomies are traditionally reserved for, but not limited to, tumors involving the primary motor and speech areas

Preclinical Studies Yield New Pathway Clues in Medulloblastoma

August 28th 2013

Since the mid-1970s, Rakesh K. Jain, PhD, has pursued an interest in the role that tumor microenvironment plays in drug delivery and efficacy.

Dr. Parsa on the Administration of the G-200 Vaccine in GBM

August 21st 2013

Andrew T. Parsa, MD, PhD, from the University of California, San Francisco, describes the administration of the prophage G-200 for patients with recurrent glioblastoma multiforme.

Dr. Roth on the Treatment of Cancers With Bevacizumab

August 15th 2013

Bruce Roth, MD, from the Siteman Cancer Center, Washington University School of Medicine, discusses the treatment of several cancers with bevacizumab.

Dr. Lesser on Armodafinil for Radiation-Induced Fatigue

August 1st 2013

Glenn J. Lesser, MD, Professor, Hematology & Oncology, Comprehensive Cancer Center, Wake Forest Baptist Health, discusses armodafinil for brain radiation-induced fatigue.

Dr. Parsa on a Trial Analyzing G-200 for Glioblastoma

July 2nd 2013

Andrew T. Parsa MD, PhD, from the University of California, San Francisco, describes the design of a trial analyzing prophage G-200 vaccine for recurrent glioblastoma multiforme.

Dr. Lesser on the Background of the RTOG 0424 Study

June 17th 2013

Glenn J. Lesser, MD, discusses the background of the RTOG 0424 study, which analyzed temozolomide in high-risk low-grade gliomas.

Dr. Gilbert Describes Ongoing RTOG 0825 Trial Analyses

June 3rd 2013

Mark R. Gilbert, MD, from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses findings from the RTOG 0825 phase III trial evaluating bevacizumab in patients with newly diagnosed glioblastoma.

First-Line Bevacizumab Does Not Improve Survival in Glioblastoma

June 2nd 2013

Adding bevacizumab to a standard treatment regimen for glioblastoma consisting of chemoradiation with temozolomide in newly diagnosed patients does not improve OS and did not significantly improve PFS.

New Mechanism of Resistance Identified in Brain Tumors

April 17th 2013

Researchers have identified a mechanism that explains why patients with glioblastoma have not had successful outcomes when treated with inhibitors of mTOR despite the fact that it is overexpressed in approximately 90% of cases.

Notch Holds Promise, but Presents Obstacles as Cancer Target

March 1st 2013

Benjamin W. Purow, MD, a researcher whose focus is on glioblastomas, discusses the Notch pathway and the development of Notch-targeted anticancer agents.